Impact of Extrarenal Myoglobin Clearance on Kidney Recovery in Severe Rhabdomyolysis
Official title: Retrospective Evaluation of the Impact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis
Run by University Hospital, Strasbourg, France · NCT07853677 · Data updated 2026-11-12
This study looks at whether removing myoglobin outside the kidney helps people with severe rhabdomyolysis recover kidney function.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | April 8, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 2, 2026 |
| Trial ID | NCT07853677 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with severe rhabdomyolysis and AKI treated at Strasbourg University Hospitals between 2015 and 2024, with available medical records and consent for data reuse.
✕Probably not a fit
Patients whose data do not show improved renal recovery or who have complex comorbidities may not benefit from these techniques.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study using retrospective clinical data from adults treated at Strasbourg University Hospitals between 2015 and 2024. It investigates the effect of extracorporeal myoglobin clearance, including mid-cut-off membranes, on renal recovery in patients with rhabdomyolysis-associated acute kidney injury. The analysis focuses on those with or without renal replacement therapy and uses existing medical records to assess outcomes. The study aims to clarify whether these dialysis-like techniques improve kidney function or recovery time in this patient population.
Why it matters
Potential benefit: If successful, findings could guide clinicians on using mid-cut-off membrane therapies to improve kidney recovery in severe rhabdomyolysis.
How similar studies have gone: Prior work supports the feasibility of extracorporeal approaches for myoglobin clearance, but their impact on renal recovery remains variably demonstrated and further evidence is needed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years). * Patient is hospitalized in the nephrology or medical intensive care units of the Strasbourg University Hospitals (NHC or Hautepierre) between 2015 and 2024. * Confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy. * Patient has not objected to the reuse of their medical data. Exclusion criteria: * Patient has objected to the reuse of their data. * Incomplete medical file preventing the complete analysis of the data necessary for the study. * Subject under guardianship, curatorship, or legal protection.
Where it's running
-
Service de Néphrologie Dialyse Transplantation - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Nans FLORENS, MD
- Email: nans.florens@chru-strasbourg.fr
- Phone: 33 3 69 55 13 25
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.